Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
In deal fraud dispute with Novo, KBP looks to revive heart drug
KBP could move to conduct another phase 3 trial, potentially pursuing a smaller indication with the FDA, according to a person close to the situation.
Angus Liu
Apr 1, 2026 2:30am
Top 10 pharma R&D budgets of 2025
Mar 30, 2026 3:00am
Scaling Radioligand Therapy: Expanding the Impact of Theranostics
Brought to you by
Curium
Lilly pays $6.3B upfront for sleep disorder-focused Centessa
Mar 31, 2026 8:53am
Fierce Pharma
Iterum initiates wind-down after failure to offload antibiotic
Mar 31, 2026 2:06pm
After FDA refusal, IO Biotech surrenders to bankruptcy
Mar 31, 2026 10:17am
More News
Ambrosia scores $100M series B to advance next-gen oral GLP-1
Mar 31, 2026 10:02am
Fierce Biotech Layoff Tracker 2026: Lipella, IO, Takeda & more
Mar 31, 2026 10:00am
BMS links up with Faro to use AI to improve trial protocols
Mar 31, 2026 9:00am
Fierce Biotech Fundraising Tracker '26: Gilgamesh, Immutrin & more
Mar 31, 2026 8:45am
See more stories